Latest Commercialisation News

Page 6 of 239
Nanollose has narrowed its microbial cellulose scale-up plan to one company-controlled Western Australian pilot facility, with all Stage 1 equipment ordered and paid for. The progress comes with a clear funding constraint: the ASX-listed biomaterials developer ended September with $758,000 in cash, equivalent to 1.41 quarters of funding at its current operating burn.
Victor Sage
Victor Sage
30 Oct 2026
OncoSil Medical enters FY27 with FDA approval for its cancer device, rising quarterly revenue and fresh institutional funding, but its U.S. opportunity still depends on reimbursement and a tightly controlled initial rollout. Cash rose to A$8.7 million after the capital raise, while operating cash use remained substantial.
Victor Sage
Victor Sage
30 Oct 2026
Bio-Gene Technology has moved closer to two commercialisation milestones, with Qcide product work progressing in Japan and a first Flavocide regulatory submission targeted for Q2 2027. The company ended September with A$2.103 million in cash, equivalent to an estimated 2.18 quarters of funding at the quarter’s operating cash rate.
Victor Sage
Victor Sage
30 Oct 2026
Algorae Pharmaceuticals has moved closer to its first expected NSW Health supply orders while reporting stronger preclinical results from its AOS2 drug-discovery platform. The company ended September with $3.15 million in cash and a further $3 million undrawn facility, but its commercial contract carries no minimum volume commitment.
Victor Sage
Victor Sage
30 Oct 2026
Hiremii’s revenue fell 11.1% to A$7.056 million in Q1 FY2027 as adjusted EBITDA slipped further into loss, testing the company’s transition towards AI-powered workforce intelligence. The new AQYR brand and two platform launches offer a growth narrative, but cash discipline remains central with A$1.789 million of total available funding.
Victor Sage
Victor Sage
30 Oct 2026
Optiscan has moved its InForm and InVue medical-imaging devices into formal US FDA review after a quarter of intensive regulatory and clinical work. The milestone comes with $11.093 million in cash and a reported 3.5 quarters of funding at the latest operating burn rate.
Victor Sage
Victor Sage
30 Oct 2026
TALi Digital closed its September quarter with $3.9 million in cash after completing a $3.3 million capital raise and winning shareholder approval for the Datasphere transaction. The company has also exercised an option to negotiate exclusive worldwide rights to Technion in-memory computing technology, although the licence remains unsigned and the technology unproven at commercial scale.
Victor Sage
Victor Sage
30 Oct 2026
Powerhouse Ventures lifted quarterly pre-tax operating profit 46% to A$340,000 despite difficult microcap conditions, while completing three advisory transactions and launching its first private venture product. The investment house ended September with A$1.40 million in cash, A$5.75 million in listed assets and an estimated six quarters of funding.
Claire Turing
Claire Turing
30 Oct 2026
Sparc Technologies has moved its graphene additive business from testing towards commercial adoption, with a first ecosparc® delivery to a tier 1 coatings manufacturer and more than 20 active qualification programs. The September quarter also delivered hydrogen progress and fresh funding, but the company reported only 1.14 quarters of cash coverage before subsequent receipts.
Sophie Babbage
Sophie Babbage
30 Oct 2026
Aurora Labs has moved another step from propulsion development toward commercial production, securing AS9100D certification and its first US engine order while customer enquiries expand. But with only A$1.148 million in cash at quarter-end and 1.5 quarters of funding estimated, the A$6 million raise is central to the next phase.
Victor Sage
Victor Sage
30 Oct 2026
Clinuvel has submitted NEURACTHEL Instant for regulatory review in three initial European Union markets, opening a potential pathway for its second pharmaceutical product. The decentralised review is expected to take 300 days, excluding clock stops, but the product is not yet approved anywhere.
Victor Sage
Victor Sage
30 Oct 2026
Environmental Clean Technologies has produced its first MXene on a US Flash Joule Heating reactor, marking a technical step in its defence materials strategy. The harder work now is proving repeatability, performance and customer qualification while building a separate PFAS pilot.
Victor Sage
Victor Sage
30 Oct 2026

Browse the archive

Full archive